Clinical Trials on Polycystic Liver Disease

Total 377195 results

Hospices Civils de Lyon

Unknown

Automatic Segmentation of Polycystic Liver (ASEPOL)

Polycystic Liver Disease | Liver Injury | Polycystic Hepatorenal Disease

France
Radboud University Medical Center

Recruiting

Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts (ATLAS)

Autosomal Dominant Polycystic Kidney | Polycystic Liver Disease | Liver Cyst | Autosomal Dominant Polycystic Liver Disease

Netherlands
Mayo Clinic

Completed

Pasireotide LAR in Severe Polycystic Liver Disease (SOM230)

Autosomal Dominant Polycystic Kidney Disease | Polycystic Liver Disease | Autosomal Dominant Polycystic Liver Disease | Somatostatin Analogs

United States
University Medical Center Groningen
Radboud University Medical Center

Recruiting

A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease (AGAINST-PLD)

Autosomal Dominant Polycystic Kidney | Polycystic Liver Disease

Netherlands
Assy Nimer

Unknown

THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS

Nonalcoholic Fatty Liver Disease | Polycystic Ovarian Syndrome,

Israel
Radboud University Medical Center
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Completed

Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease (CURSOR)

Polycystic Kidney, Autosomal Dominant | Polycystic Liver Disease

Netherlands, Spain
Radboud University Medical Center
Novartis

Completed

Everolimus and LongActing Octreotide Trial in Polycystic Livers (ELATE)

Polycystic Liver Disease

Netherlands
Mayo Clinic

Recruiting

A Prospective Observational Study of Foam Sclerotherapy .

Autosomal Dominant Polycystic Kidney | Autosomal Dominant Polycystic Liver Disease | Renal Cyst | Hepatic Cyst

United States
Radboud University Medical Center
Ipsen

Completed

Lanreotide as Treatment of Polycystic Livers (LOCKCYST)

Liver Diseases | Polycystic Kidney, Autosomal Dominant | Hepatomegaly | Polycystic Liver Disease

Netherlands, Belgium
Radboud University Medical Center
Ipsen

Unknown

Open-Label Extension of LOCKCYST Trial (LOCKCYST-ext)

Liver Diseases | Hepatomegaly | Polycystic Liver Disease | Polycystic Kidney | Autosomal Dominant

Netherlands, Belgium
Camurus AB

Active, not recruiting

A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD (POSITANO)

Polycystic Liver Disease

United States, Germany, Belgium, Netherlands
National Taiwan University Hospital

Enrolling by invitation

The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease

Polycystic Kidney Diseases | Muscle Loss | Polycystic Liver Disease

Taiwan
Portsmouth Hospitals NHS Trust
Radboud University Medical Center

Recruiting

Polycystic Liver Disease Registry (UK) (PLD)

Polycystic Liver Disease

Netherlands, United Kingdom
Universitaire Ziekenhuizen KU Leuven
Ipsen

Completed

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease (LOCKCYST)

Polycystic Liver Disease

Belgium
Mayo Clinic
Novartis; National Center for Research Resources (NCRR)

Completed

Octreotide in Severe Polycystic Liver Disease

Liver Diseases | Abdominal Pain | Polycystic Kidney, Autosomal Dominant | Hepatomegaly | Polycystic Liver Disease | Kidney, Polycystic

United States
Radboud University Medical Center
Ipsen

Completed

Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE) (RESOLVE)

Polycystic Liver Disease

Netherlands
Mayo Clinic
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Polycystic Liver Disease in Kidney Transplant

Polycystic Liver Disease

United States
University of Colorado, Denver

Completed

Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS (ORANGE)

Obesity | Polycystic Ovarian Syndrome | Hepatic Steatosis

United States
Mayo Clinic

Recruiting

Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).

Polycystic Liver Disease

United States
Palladio Biosciences
Centessa Pharmaceuticals plc

Terminated

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ALERT)

ADPKD | Polycystic Kidney Disease, Adult

United States
Emory University
PKD Foundation

Completed

ADPKD Cohort Study

Autosomal Dominant Polycystic Kidney Disease

United States
Hacettepe University

Completed

Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome

PCOS | NAFLD

Turkey
University of North Carolina, Chapel Hill
National Institute of General Medical Sciences (NIGMS)

Completed

ADPKD Alterations in Hepatic Transporter Function

Renal Disease | Autosomal Dominant Polycystic Kidney Disease | ADPKD

United States
Kadmon Corporation, LLC

Terminated

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States
Kyorin University

Unknown

Efficacy of Tolvaptan on ADPKD Patients

Autosomal Dominant Polycystic Kidney Disease

Japan
Assistance Publique - Hôpitaux de Paris
IPSEN pharmaceutical company, Boulogne-Billancourt, France

Completed

Lanreotide In Polycystic Kidney Disease Study (LIPS)

Autosomal Dominant Polycystic Kidney Disease (ADPKD

France
Cambridge University Hospitals NHS Foundation Trust
Addenbrookes Charitable Trust; PKD Charity; British Renal Society & British Kidney...

Completed

High Water Intake in Polycystic Kidney Disease (DRINK)

Autosomal Dominant Polycystic Kidney Disease

United Kingdom
University of Pittsburgh
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Completed

Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP II)

Autosomal Dominant Polycystic Kidney Disease

United States
Andreas L. Serra

Unknown

The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe

Autosomal Dominant Polycystic Kidney Disease

France, Switzerland, Germany, Netherlands, Belgium, Czech Republic, Italy, Spain, Turkey, United Kingdom
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Intrarenal Microvasculature in ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
Mario Negri Institute for Pharmacological Research
Otsuka Pharmaceutical Italy S.r.l.

Completed

Tolvaptan-Octreotide LAR Combination in ADPKD (TOOL)

Autosomal Dominant Polycystic Kidney Disease

Italy
Mayo Clinic
University of Kansas Medical Center

Completed

Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
CHU de Reims

Completed

ADPKD and Peritoneal Dialysis: How Anticipate Peritoneal Pressure? (PDP-ADPKD)

Autosomal Dominant Polycystic Kidney Disease

France
Otsuka Pharmaceutical Development & Commercialization...

Completed

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
Regional Hospital Holstebro
Aarhus University Hospital

Completed

Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TOPO)

Autosomal Dominant Polycystic Kidney Disease

Denmark
University Hospital, Brest

Unknown

Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease) (GENKYST)

Autosomal Dominant Polycystic Kidney Disease

France
Federico II University

Completed

Effects of Somatostatin on Liver in ADPKD

Autosomal Dominant Polycystic Kidney Disease
Tufts Medical Center

Completed

Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States
Otsuka Pharmaceutical Europe Ltd

Unknown

A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe (ACQUIRE)

Autosomal Dominant Polycystic Kidney Disease

Spain, United Kingdom, Germany, France, Belgium, Switzerland, Austria
Federico II University

Completed

Effects of Somatostatin on ADPKD Heart

Autosomal Dominant Polycystic Kidney Disease | Glomerular Filtration Rate > 40 ml/Min
University Medical Center Groningen
Radboud University Medical Center; Erasmus Medical Center; Leiden University...

Unknown

Study of Lanreotide to Treat Polycystic Kidney Disease (DIPAK1)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Netherlands
Mario Negri Institute for Pharmacological Research

Completed

Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study (ALADIN)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Italy
CHU de Reims

Completed

Outcome of Autosomal Dominant Polycystic Kidney Disease Patients on Peritoneal Dialysis: a National Retrospective Study Based on Two French Registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network). (ADPKDPD)

Polycystic Kidney Diseases

France
Palladio Biosciences
Centessa Pharmaceuticals plc

Terminated

Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303

Polycystic Kidney Disease, Adult

United States
Vertex Pharmaceuticals Incorporated

Not yet recruiting

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants

Autosomal Dominant Polycystic Kidney Disease (ADPKD)
The University of Queensland

Recruiting

Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

Autosomal Dominant Polycystic Kidney Disease

Australia
Mayo Clinic
Polycystic Kidney Disease Foundation

Recruiting

NOX4 and Related Biomarkers in ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
University of Cologne

Recruiting

The German ADPKD Tolvaptan Treatment Registry (AD(H)PKD)

ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Germany
Regulus Therapeutics Inc.

Completed

A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney Disease, Autosomal Dominant

United States
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (TEMPO3:4)

Polycystic Kidney Disease, Autosomal Dominant

United States, Belgium, United Kingdom, Russian Federation, France, Australia, Netherlands, Italy, Japan, Denmark, Romania, Poland, Canada, Argentina, Germany

Clinical Trials on Polycystic Liver Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations